-
公开(公告)号：US20230407403A1
公开(公告)日：2023-12-21
申请号：US18036733
申请日：2021-11-08
发明人： Takaya Shimura , Yusuke Okuda , Hiromi Kataoka
IPC分类号： C12Q1/6886
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N2800/52
摘要： The present invention provides a versatile method which has a high diagnostic accuracy rate on the suitability of esophageal cancer for endoscopic therapy and enables the simple and objective determination of the suitability or unsuitability for endoscopic therapy.
In the method according to one aspect of the present invention, an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject is measured, and the expression level is compared with a reference value; the diagnostic kit according to one aspect of the present invention comprises a reagent for measuring at least one or more selected from the group consisting of the expression level of CXCL2 in the sample and the expression level of VEGFA in the sample; in the method for treating esophageal cancer according to one aspect of the present invention, the degree of vertical invasion of esophageal cancer in a subject is determined by employing a method in which an expression level of at least one or more selected from the group consisting of CXCL2 and VEGFA in a sample collected from a subject is measured and the expression level is compared with a reference value.-
公开(公告)号：US11447569B2
公开(公告)日：2022-09-20
申请号：US15555808
申请日：2016-03-07
申请人： PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY , PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY , PHARMA FOODS INTERNATIONAL CO., LTD.
发明人： Mamoru Sato , Michiyuki Yamada , Satoshi Kanazawa , Masayoshi Toyoura , Yuji Shoya , Kenji Saito , Chihiro Yamazaki
摘要： Provided are anti-PAD4 antibodies having excellent properties and an excellent method for treatment of RA. Used are anti-PAD4 antibodies that specifically bind to an epitope containing positions 345, 347, and 348 of PAD4. These anti-PAD4 antibodies may inhibit the citrullination activity of PAD4. In addition, these anti-PAD4 antibodies may have a KD (M) of 9.0×10−9 or less. Optionally, the anti-PAD4 antibody and a TNFα inhibitor are used in combination.
-
公开(公告)号：US20220290249A1
公开(公告)日：2022-09-15
申请号：US17635295
申请日：2020-08-12
发明人： Takaya SHIMURA , Hiroyasu IWASAKI , Hiromi KATAOKA
IPC分类号： C12Q1/6886
摘要： The present invention provides a colorectal cancer diagnostic marker which can determine the presence or absence of colorectal cancer with high accuracy and which can also detect early-stage colorectal cancer with high sensitivity; a method which is for assisting the diagnosis of colorectal cancer, and measures an expression level of the colorectal cancer diagnostic marker; a method for collecting data for diagnosis of colorectal cancer; a method for diagnosing colorectal cancer; a method for treating colorectal cancer; a colorectal cancer diagnostic kit including a primer that is specific to the colorectal cancer diagnostic marker; and a therapeutic agent for colorectal cancer containing an inhibitor of the colorectal cancer diagnostic marker.
The colorectal cancer diagnostic marker of the present invention is at least one microRNA selected from a group consisting of hsa-miR-129-1-3p, hsa-miR-566, and hsa-miR-598-5p.-
公开(公告)号：US11338153B2
公开(公告)日：2022-05-24
申请号：US16387006
申请日：2019-04-17
发明人： Akimichi Morita , Katsutoshi Sakano
IPC分类号： A61N5/06
摘要： Provided is a phototherapeutic apparatus including: a probe that is held and operated by a user and provided with a photo-irradiation unit that performs irradiation with light beams; and a body provided with a control unit that controls the light beams. The body is provided with a read unit that reads a treatment protocol registered in an IC card (mobile memory medium), and a monitor (operation indication unit) that indicates a region to be irradiated with the light beams to the user, the region being set in the treatment protocol, and the control unit causes the monitor to indicate the region to be irradiated and causes the photo-irradiation unit to perform the irradiation with the light beams at a set value set in the treatment protocol. It is possible to perform the irradiation with the light beams in accordance with the treatment protocol and safely use the phototherapeutic apparatus.
-
公开(公告)号：US20220125854A1
公开(公告)日：2022-04-28
申请号：US17436205
申请日：2020-02-12
摘要： It is a subject to provide a means of preparing highly pure vascular endothelial progenitor cells in a simple and low-cost manner. It is also a subject to provide a method for efficiently proliferating vascular endothelial progenitor cells. High-purity vascular endothelial progenitor cells are prepared by the process of differentiating pluripotent stem cells into vascular endothelial progenitor cells and purifying the vascular endothelial progenitor cells using a difference in adhesion ability between the vascular endothelial progenitor cells constituting the cell population obtained in the process and other cells. On the other hand, vascular endothelial progenitor cells are cultured and expanded in the presence of a ROCK inhibitor, a GSK-3β inhibitor, and a TGF-β receptor inhibitor in addition to basic fibroblast growth factor and epidermal growth factor.
-
公开(公告)号：US20220033780A1
公开(公告)日：2022-02-03
申请号：US17290446
申请日：2019-10-31
发明人： Tamihide MATSUNAGA , Takahiro IWAO , Daichi ONOZATO , Isamu OGAWA
摘要： An object is to prepare an intestinal organoid having a characteristic close to the small intestine of a living body, from a pluripotent stem cell. An intestinal organoid is prepared from a pluripotent stem cell, by the following steps of: (1) differentiating the pluripotent stem cell into an endoderm-like cell; (2) differentiating the endoderm-like cell obtained in step (1) into an intestinal stem cell-like cell; (3) culturing the intestinal stem cell-like cell obtained in step (2) in the presence of an epidermal growth factor, a fibroblast growth factor, a TGF β receptor inhibitor, a GSK-3 β inhibitor, and a ROCK inhibitor; (4) culturing the cell obtained in step (3) to form a spheroid; and (5) differentiating the spheroid formed in step (4) to form an intestinal organoid, wherein the differentiation includes culturing in the presence of an epidermal growth factor, a BMP inhibitor, and a Wnt signal activator. Also, a plane culture system is prepared by subjecting the cells constituting the intestinal organoid formed in step (5) to plane culture in the presence of an epidermal growth factor and a TGF β receptor inhibitor. A highly functional evaluation system having the villi structure is constructed by using air-liquid interface culture in the plane culture.
-
公开(公告)号：US20190099366A1
公开(公告)日：2019-04-04
申请号：US16094506
申请日：2017-04-19
发明人： Tsutomu Yasukawa
摘要： An object of the present invention is to provide a sustained drug release system useful for treating eye diseases. There is provided a device for sustained release of an ophthalmic drug, comprising a drug enclosing part and an intraocular retention gas enclosing part adjacent to the drug enclosing part, the enclosing parts being provided in a hollow container having at least one opening part, wherein the drug enclosing part is isolated from the opening part by the intervention of the intraocular retention gas enclosing part.
-
8.发明申请公开(公告)号：US20190079076A1
公开(公告)日：2019-03-14
申请号：US16083226
申请日：2017-03-03
发明人： Takahiro Iwao , Tomoki Kabeya , Tamihide Matsunaga
摘要： An object of the present invention is to provide a novel method which enables convenient preparation of cells exhibiting functions close to that of intestinal epithelial cells of living bodies, and use of the method. The differentiation of induced pluripotent stem cells into intestinal epithelial cells is induced by step of differentiating induced pluripotent stem cells into endoderm-like cells; step of differentiating the endoderm-like cells obtained in step into intestinal stem cell-like cells; and step of differentiating the intestinal stem cell-like cells obtained in step into intestinal epithelial cell-like cells, wherein step includes culture in the presence of a MEK1 inhibitor, a DNA methyltransferase inhibitor, a TGF-β receptor inhibitor, and EGF and under the condition that cAMP is supplied to the cells.
-
公开(公告)号：US20240070501A1
公开(公告)日：2024-02-29
申请号：US18027004
申请日：2021-09-16
发明人： Takahiro MATSUMOTO , Akio TOKUMITSU
摘要： A quantum entanglement device includes a group-IV semiconductor, and a scissor-type quantum entanglement element that has at least one atom on a surface of the group-IV semiconductor and two hydrogen atoms or two deuterium atoms coupled to terminations of the atom.
-
公开(公告)号：US20230147040A1
公开(公告)日：2023-05-11
申请号：US17918704
申请日：2021-04-01
发明人： Motoki NAKAMURA
IPC分类号： G01N33/574 , C12Q1/26 , G01N33/50 , C12Q1/6886
CPC分类号： G01N33/5743 , C12Q1/26 , C12Q1/6886 , C12Y101/01049 , G01N33/5011 , C12Q2600/118 , C12Q2600/158 , G01N2333/904
摘要： Provided is a technique of predicting prognosis of skin cancer. A method for prognosis prediction of skin cancer includes: a step of obtaining a correlation amount correlated with an expression level of a glucose-6-phosphate dehydrogenase in a sample collected from a patient with the skin cancer; and a step of determining that the prognosis of the skin cancer is poorer when the correlation amount is large than that when the correlation amount is small.
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.019 秒)
